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Abstract
Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) are colloidal carrier systems providing controlled
release profiles for many substances. Clotrimazole-loaded SLN and NLC were prepared by the hot high pressure homogenization
technique in order to evaluate the physical stability of these particles, as well as the entrapment efficiency of this lipophilic drug
and its in vitro release profile. The particle size was analyzed by PCS and LD showing that the particles remained in their colloidal
state during 3 months of storage at 4, 20 and 40 ◦C. For all tested formulations the entrapment efficiency was higher than 50%.
The obtained results also demonstrate the use of these lipid nanoparticles as modified release formulations for lipophilic drugs
over a period of 10 h.
© 2004 Elsevier B.V. All rights reserved.
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1. Introduction
Solid lipid nanoparticles (SLNTM) were developed
at the beginning of the 1990s as an alternative car-
rier system to the existing traditional carriers, such
as emulsions, liposomes and polymeric nanoparticles
(Müller and Lucks, 1996). The major advantage of
SLN is the possibility of production on large indus-
trial scale (Müller et al., 2000a). However, depending
on the drug some potential problems can occur, such
as drug leakage during storage and insufficient total
drug load. To overcome the limitations of SLN, nanos-
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tructured lipid carriers (NLCTM) have been developed
(Müller et al., 2000b,c). The later consist of a solid
lipid matrix with a high content of liquid lipid (Radke,
2003).
Both SLN and NLC possess a number of features
advantageous for the topical route of application
(Müller et al., 1995, 2000d, 2002; Mehnert and Mäder,
2001). These carriers are composed of physiological
and biodegradable lipids of low systemic toxicity and
also low cytotoxicity (Müller et al., 1997). Most of
the used lipids have an approved status or are excipi-
ents used in commercially available topical cosmetic
or pharmaceutical preparations. The small size of the
lipid particles ensures close contact to the stratum
corneum and can increase the amount of the drug
penetrating into the mucosa or skin. Due to their solid
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lipid matrix, controlled release from these carriers is
possible. This becomes an important tool when it is
necessary to supply the drug over a prolonged pe-
riod of time and to reduce systemic absorption, and
when the drug is irritating at high concentrations. As
a result of film formation after topical application
occlusive properties were also reported (Müller et al.,
2002; Wissing and Müller, 2001, 2002a; Wissing
et al., 2001).
Clotrimazole was used as a highly lipophilic model
drug in the present study. The aim of this work was
focused on drug release and occlusive properties of
clotrimazole-loaded SLN and NLC. In order to assess
the in vitro release pattern of the drug from these carri-
ers, the recommended Franz diffusion cells were used.
2. Materials
Dynasan®116 (glyceryl tripalmitate) was pur-
chased from Contensio Chemicals GmbH (Wit-
ten, Germany), tyloxapol was provided by Sigma
Aldrich (Deisenhofen, Germany) and clotrimazole
and Miglyol®812 were obtained from Caelo, Ger-
many. The materials were used as received. Water
was used in double-distilled quality.
3. Methods
3.1. Production of SLN and NLC
Glyceryl tripalmitate (Dynasan®116) SLN were
produced by the hot homogenization technique with
a high pressure homogenizer APV Micron Lab 40
(APV Deutschland GmbH, Lübeck, Germany). The
lipid was heated up to 90 ◦C and 5% of clotrima-
zole (related to the lipid matrix) was added to the
melted Dynasan®116. The hot lipid phase was dis-
persed in the hot surfactant solution (90 ◦C), using
an Ultra-Turrax T25 (Jankle & Kunkel GmbH and
Co KG, Staufen, Germany) at 8000 rpm for 1 min.
The obtained pre-emulsion was then homogenized
at 90 ◦C by high pressure homogenization applying
three homogenization cycles at 500 bar.
Glyceryl tripalmitate (Dynasan®116) NLC were
prepared in exactly the same manner as the SLN
dispersions, only partially replacing 30% of the solid
lipid matrix by Miglyol®812 (caprylic/capric triglyc-
erides).
3.2. Particle sizing and drug entrapment efficiency
Particle size was analyzed by photon correlation
spectroscopy (PCS) with a Zetasizer 4 (Malvern In-
struments, UK) and by laser diffractometry (LD), us-
ing a Coulter®LS 230 (Coulter Electronics, Germany).
PCS yields the mean particle size and the polydisper-
sity index (PI) as a measure of the width of the distri-
bution. The LD data were evaluated using the diameter
90% (d90%), which means that 90% (volume distribu-
tion) of the measured particles are below this value.
The percentage of incorporated clotrimazole (en-
trapment efficiency) was determined by spectropho-
tometric determination at 243 nm using an Uvikon
940 (Kontron Instruments, Eching, Germany), after
centrifugation of the aqueous dispersion. The amount
of free drug was detected in the supernatant and the
amount of incorporated drug was determined as a re-
sult of the initial drug minus the free drug. The entrap-
ment efficiency could be calculated by the following
equation:
EE (%) =
(
Winitial drug −Wfree drug
Winitial drug
)
× 100
where “Winitial drug” is the mass of initial drug used for
the assay and the “Wfree drug” is the mass of free drug
detected in the supernatant after centrifugation of the
aqueous dispersion.
3.3. Release studies
The release studies were performed with static
Franz diffusion cells (0.9 cm in diameter, Crown
Scientific, Sommerville, USA). The diffusion cells
were thermoregulated with a water jacket at 32 ◦C.
Cellulose nitrate (0.1m pore diameter, Sartorius,
Göttingen, Germany) membrane filters were mounted
to Franz diffusion cells. Acetate buffer (pH 6.0) with
35% of dioxan was used as receptor fluid. 100l of
SLN or NLC aqueous dispersion (containing 1% of
clotrimazole) was applied to the donor compartment.
Samples (250l) were collected over 24 h and ana-
lyzed by spectrophotometric determination at 243 nm
E.B. Souto et al. / International Journal of Pharmaceutics 278 (2004) 71–77 73
using an Uvikon 940 (Kontron Instruments). The
release studies were performed in triplicate.
3.4. Occlusion test
The in vitro occlusion test was adapted by de
Vringer (1992). Beakers (100 ml) were filled with
50 ml of water, covered with filter paper (cellulose ac-
etate filter, 90 mm, Schleicher, Germany; cutoff size:
4–7m) and sealed. 200 mg of sample was spread
evenly with a spatula on the filter surface (18.8 cm2),
leading to an applied amount of 10.6 mg/cm2. A vis-
ible film formation on top of the filter paper was
observed during the experiment. The samples were
stored at 32 ◦C (skin temperature) and 50–55% r.h.
for 48 h. The samples were weighed after 6, 24 and
48 h, giving the water loss due to evaporation at each
time (water flux through the filter paper). Beakers
covered with filter paper but without applied sam-
ple served as reference values. Every experiment
was performed in triplicate (n = 3). The occlusion
factor F was calculated according to the following
equation:
F =
(
A− B
A
)
× 100
where A is the water loss without sample (reference)
and B is the water loss with sample. An occlusion
factor of 0 means no occlusive effect compared to the
reference and 100 is the maximum occlusion factor.
4. Results and discussion
4.1. Characterization of the investigated
formulations
Three different types of lipid particles were pro-
duced by hot high pressure homogenization. The com-
position of the investigated formulations is shown in
Table 1
Composition of the investigated SLN and NLC formulations (%, w/w)
Formulation Dynasan®116 Tyloxapol Clotrimazole Miglyol®812
A (SLN) 9.5 3 0.5 –
B (SLN) 19 5 1 –
C (NLC) 13.5 5 1 5.5
Table 1. After production the aqueous dispersions were
stored at three different temperatures (4, 20 and 40 ◦C)
and their particle size was measured during 3 months.
Fig. 1 shows the LD mean diameters (d90%) after
1, 60 and 90 days of storage and Fig. 2 shows the
PCS mean diameters and the polydispersity index (PI)
after 90 days at 4, 20 and 40 ◦C. For all formulations
the d90% measured by LD was below 0.5m at room
temperature. The batches stored at 4 ◦C show higher
particle sizes, but also in the nanometer range. The
PCS measurements show that the particle size remains
lower than 300 nm, 3 months after production. It could
also be observed that the particle size increased with
the increase of lipid concentration.
4.2. Entrapment efficiency
SLN are prepared from solid lipids or blends of
solid lipids. After hot high pressure homogenization
the lipid recrystallizes in higher energy modifications,
i.e. - and -forms (Westesen et al., 1993). During
storage, these polymorphic forms can transform to a
more ordered modification (), which is characterized
by a lower energy modification and a higher degree of
crystallinity. These parameters are strongly correlated
with drug incorporation (Bunjes et al., 1996). Drug
expulsion in SLN can occur when the lipid matrix
transforms from high energy modifications, charac-
terized by the presence of many imperfections, to the
-modification forming a perfect crystal with no room
for guest molecules. This phenomenon is even more
pronounced when high purity lipids are used. To over-
come this problem, NLC have been developed. The
lipid matrix of these particles is constituted by solid
lipids and liquid lipids, which can be mixed in such a
combination that the particle solidifies upon cooling
but does not recrystallize and remains in the amor-
phous state. A second type of NLC is formed when
the lipid molecules are chemically very different,
resulting in a structure with many imperfections to
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Fig. 1. Particle size (m) of SLN (A and B) and NLC (C) formulations measured by LD (d90%) after 1, 60 and 90 days of storage at 4,
20 and 40 ◦C.
accommodate the drug and thus higher loading ca-
pacity (Fig. 3).
The percentage of incorporated drug in the lipid
matrix (entrapment efficiency) was evaluated over a
period of 21 days. The results are shown in Fig. 4.
Incorporation of clotrimazole led to high entrapment
efficiency, probably because of their lipophilic char-
acter. NLC formulation (C) is responsible for a higher
entrapment efficiency in comparison to both SLN for-
mulations (A and B). This result is due to the binary
mixture of liquid and solid lipids, resulting in only a
very weak crystallization (Jenning et al., 2000a,b).For
SLN formulations, the entrapment efficiency is lower
Fig. 2. Diameter (nm) and polydispersity index (PI) of SLN (A and B) and NLC (C) formulations measured by PCS after 90 days of
storage at 4, 20 and 40 ◦C.
for the sample with lower lipid concentration. It has
to be noticed that during the cooling process after
homogenization, the lipid solidifies and the drug is
distributed into the shell of the particles, if the con-
centration of the drug in the melted lipid is well be-
low its saturation solubility. As a result, SLN show a
drug-enriched shell model (Formulation A, Fig. 5). A
drug-enriched core model (Formulation B, Fig. 5) is
formed when the drug in the melted lipid is closed to
its saturation solubility. The cooling process leads to
supersaturation of the drug and subsequently to drug
crystallization prior to lipid crystallization (Wissing
and Müller, 2002b).
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Fig. 3. Formation of a perfect lipid crystal in SLN and a crystal lattice with many imperfections in NLC.
Fig. 4. Entrapment efficiency (EE) of clotrimazole in different SLN (A and B) and NLC (C) formulations, calculated after 1, 7 and 21
days of storage at room temperature.
4.3. In vitro release studies
In order to evaluate the controlled release poten-
tial of the investigated formulations, the diffusion of
Fig. 5. Models of incorporation of active compound into
SLN. Lipid core with compound-enriched outer shell (left),
drug-enriched core with lipid shell (right).
clotrimazole from the lipid particles was investigated
over 24 h. Each sample was analyzed in triplicate. The
results are shown in Fig. 6.
The release rate of clotrimazole depends on the
total concentration of drug in the formulation. Clotri-
mazole is released more quickly when using lower
concentration because of the drug-enriched shell
model proposed for these particles (Formulation A).
Due to the large drug loading in Formulation B, the
degree of diffusion can be decreased. On the contrary,
due to the liquid structure of NLC, the formulation C
shows a faster release.
4.4. Occlusion test
As reported above, lipid nanoparticles show ad-
hesive properties, i.e. they tend to adhere to cells
and surfaces, and due to the film formation of the
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Fig. 6. Release profile of clotrimazole of SLN (A and B) and NLC (C) formulations stored at room temperature.
Fig. 7. Occlusion factors of the investigated SLN (A and B) and NLC (C) formulations.
nanoparticles on the skin, SLN possess occlusive
properties (Wissing et al., 2001; de Vringer, 1992;
Jenning et al., 1999; Müller and Dingler, 1998). It
could be stated that the drug released from a con-
ventional formulation is accumulated in the stratum
corneum over the time course. This phenomenon of-
fers the possibility to enhance the drug’s therapeutic
index (Jenning et al., 1999).
As reported by Wissing et al. (2001), the occlusion
factor is dependent upon the sample volume, particle
size and crystallinity; therefore, samples of 200 mg
were applied to the membrane of Franz cells. The
results of the occlusion test are shown in Fig. 7.
According to Wissing et al. (2001), the occlusion
factor depends strongly on the lipid concentration and
the particle size of SLN. Our results show a lower F
for SLN containing lower lipid concentration (Formu-
lation A). For the same lipid concentration (Formu-
lations B and C) a lower occlusivity can be detected
for NLC than for SLN. This result is due to the solid
state of the lipid matrix of SLN, which disables the
evaporation of water.
5. Conclusions
This study indicates that both SLN and NLC are
potential carriers systems for topical delivery of clotri-
mazole. After 3 months of storage at different temper-
atures the mean diameters of SLN and NLC remain
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practically the same (<1m), which emphasizes the
physical stability of these lipid particles.
The entrapment efficiency and the drug release pro-
file depend on the concentration and the lipid mixture
employed. NLC show a higher entrapment efficiency
due to their liquid parts. In agreement to this results
NLC also show a faster release profile in comparison
to SLN with the same lipid concentration. The release
rate decreases for SLN with a higher lipid concentra-
tion, which is explained by the physical morphology
of the lipid particles.
Finally, it can also be concluded that SLN show a
higher occlusive capacity in comparison to NLC with
the same lipid content.
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